5 Key Takeaways

• 1

  High costs, complex workflows, specialized labor, and biological variability make consistent, large-scale cell and gene therapy manufacturing difficult.

• 2

  Developers increasingly prioritize scalability, manufacturability, supply chain robustness, and commercial viability earlier in development.

• 3

  Technology transfer, reproducibility, operator training, raw material variability, documentation, and GMP execution complicate the move to commercial manufacturing.

• 4

  Advances in cell culture media and process development can improve cell growth, productivity, and consistency across production scales.

• 5

  Automation, reliable supplies, and emerging in vivo approaches such as CAR-T and self-amplifying RNA may shape future manufacturing strategies.